Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy Cara Therapeutics stock | $13.73

Own Cara Therapeutics stock in just a few minutes.

Posted

Fact checked

Cara Therapeutics, Inc is a biotechnology business based in the US. Cara Therapeutics shares (CARA) are listed on the NASDAQ and all prices are listed in US Dollars. Cara Therapeutics employs 72 staff and has a trailing 12-month revenue of around USD$24 million.

How to buy shares in Cara Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Cara Therapeutics Find the stock by name or ticker symbol: CARA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cara Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$13.73, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Cara Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Cara Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Cara Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Cara Therapeutics's share price has had significant negative movement.

Its last market close was USD$13.73, which is 20.31% down on its pre-crash value of USD$17.23 and 54.62% up on the lowest point reached during the March crash when the shares fell as low as USD$8.88.

If you had bought USD$1,000 worth of Cara Therapeutics shares at the start of February 2020, those shares would have been worth USD$678.09 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$841.79.

Cara Therapeutics share price

Use our graph to track the performance of CARA stocks over time.

Cara Therapeutics shares at a glance

Information last updated 2020-09-20.
Latest market closeUSD$13.73
52-week rangeUSD$8.88 - USD$26.67
50-day moving average USD$15.9585
200-day moving average USD$15.4238
Wall St. target priceUSD$33.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.166

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Available asset types Stock trade fee Option trade fee Annual fee
Vanguard
Stocks,Mutual funds,ETFs,Forex
$0
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
Stocks,Options,ETFs,Cryptocurrency
$0
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
TD Ameritrade
Stocks,Bonds,Options,Mutual funds,ETFs,Forex,Futures
$0
or $25 If it is broker-assisted
$0 + $0.65/contract, Broker-assisted
or $25 Broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Interactive Brokers
Stocks,Bonds,Options,Mutual funds,Index funds,ETFs,Forex,Futures,Cash
$0
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
Stocks,Options,ETFs,Futures
$0
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cara Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cara Therapeutics price performance over time

Historical closes compared with the last close of $13.73

1 week (2020-09-14) -11.42%
1 month (2020-08-24) -10.96%
3 months (2020-06-20) N/A
6 months (2020-03-23) 24.14%
1 year (2019-09-20) -38.04%
2 years (2018-09-21) -40.77%
3 years (2017-09-21) 4.17%
5 years (2015-09-21) -34.34%

Cara Therapeutics financials

Revenue TTM USD$24 million
Gross profit TTM USD$-93,934,000
Return on assets TTM -47.25%
Return on equity TTM -96.01%
Profit margin 0%
Book value $3.007
Market capitalisation USD$681.3 million

TTM: trailing 12 months

Shorting Cara Therapeutics shares

There are currently 4.0 million Cara Therapeutics shares held short by investors – that's known as Cara Therapeutics's "short interest". This figure is 11.9% up from 3.6 million last month.

There are a few different ways that this level of interest in shorting Cara Therapeutics shares can be evaluated.

Cara Therapeutics's "short interest ratio" (SIR)

Cara Therapeutics's "short interest ratio" (SIR) is the quantity of Cara Therapeutics shares currently shorted divided by the average quantity of Cara Therapeutics shares traded daily (recently around 364972.61146497). Cara Therapeutics's SIR currently stands at 10.99. In other words for every 100,000 Cara Therapeutics shares traded daily on the market, roughly 10990 shares are currently held short.

However Cara Therapeutics's short interest can also be evaluated against the total number of Cara Therapeutics shares, or, against the total number of tradable Cara Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cara Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Cara Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.0914% of the tradable shares (for every 100,000 tradable Cara Therapeutics shares, roughly 91 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Cara Therapeutics.

Find out more about how you can short Cara Therapeutics stock.

Cara Therapeutics share dividends

We're not expecting Cara Therapeutics to pay a dividend over the next 12 months.

Have Cara Therapeutics's shares ever split?

Cara Therapeutics's shares were split on a 1:2 basis on 16 January 2014. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cara Therapeutics shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Cara Therapeutics shares which in turn could have impacted Cara Therapeutics's share price.

Cara Therapeutics share price volatility

Over the last 12 months, Cara Therapeutics's shares have ranged in value from as little as $8.88 up to $26.67. A popular way to gauge a stock's volatility is its "beta".

CARA.US volatility(beta: 1.7)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cara Therapeutics's is 1.7012. This would suggest that Cara Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cara Therapeutics overview

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site